To the Editor.—
Infection in man with several leishmania species results in a broad spectrum of clinical manifestations falling into three general categories: simple cutaneous disease, visceral or diffuse cutaneous leishmaniasis, and mucocutaneous leishmaniasis.The latter constitutes a serious clinical condition because of the involvement of the upper respiratory tract with important necrosis of soft tissue.1 As conventional therapy with pentavalent antimonials is of limited effectiveness, the need exists to develop new therapeutic modalities. We discuss the successful treatment of a patient with antimonyresistant mucocutaneous leishmaniasis with combined administration of recombinant interferon gamma and pentavalent antimonials.
Report of a Case.—
In October 1989, a 52-year-old man with an 11-year history of American mucocutaneous leishmaniasis was admitted to the hospital because an ulcerative process in the upper lip, cough, weight loss, and difficulties in swallowing. The patient, who visited from northern Argentina, was first seen in 1978 with a small
Bottasso O, Cabrini J, Falcoff R, Falcoff E. Successful Treatment of an Antimony-Resistant American Mucocutaneous Leishmaniasis: A Case Report. Arch Dermatol. 1992;128(7):996–997. doi:10.1001/archderm.1992.01680170132029
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: